Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Cerebrolysin · FPE 1070

Other · developed by Ever Neuro Pharma GmbH

Phase 4 Most advanced trial
1 Registered trials

What is Cerebrolysin?

Cerebrolysin is studied in hemorrhagic stroke when initiated within 6 hours of symptom onset.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
FPE 1070
Drug type
Other
Therapy area
Neurology
Developer
Ever Neuro Pharma GmbH
In trials of
CAH
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 4
UNII
37KZM6S21G

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06899464 Phase 4 Intracerebral Hemorrhage Not yet recruiting CAH

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hemorrhagic StrokeHemorrhagic Stroke, IntracerebralIntracerebral HemorrhageStroke

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.